Hinge Health, Inc.
HNGE
$87.35
-5.92%
Hinge Health, Inc. is a digital healthcare company providing a technology platform for treating and preventing joint and muscle pain, leveraging AI-powered motion tracking to deliver virtual physical therapy and musculoskeletal (MSK) care. As a pioneer in the digital MSK therapy market, Hinge Health differentiates itself through its proprietary patient movement data, which creates a sustainable competitive moat in a rapidly growing sector. The current investor narrative centers on the company's accelerating revenue growth, recent transition to profitability, and the potential for its AI-driven platform to capture a significant share of the expanding digital health market, as highlighted by recent analyst coverage and news articles emphasizing its high-growth prospects.…
HNGE
Hinge Health, Inc.
$87.35
Related headlines
Investment Opinion: Should I buy HNGE Today?
Based on the analysis, HNGE is rated a Buy. The company's accelerating revenue growth, improving profitability, and strong analyst support justify the premium valuation. The average analyst target of $106.47 implies 20.4% upside, and the high target of $140 suggests even greater potential. The thesis is supported by the company's AI moat and market leadership in digital MSK care.
Sign up to view all
HNGE 12-Month Price Forecast
The AI assessment is bullish, given the strong fundamental performance and growth prospects. The company's AI-driven platform and proprietary data create a competitive edge. However, the high valuation and volatility warrant a medium confidence level. I would upgrade to high confidence if the company sustains growth above 50% and expands margins further, or downgrade to neutral if growth decelerates below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $106.47 and implied upside of +21.9% versus the current price.
Average Target
$106.47
0 analysts
Implied Upside
+21.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $140
Analyst target range
The target price range spans from $85.00 (low) to $140.00 (high), indicating a wide spread of 64.7% from low to high, which reflects significant uncertainty about the company's future growth trajectory. The high target of $140 assumes continued rapid revenue growth and margin expansion, potentially driven by AI-driven market share gains, while the low target of $85 suggests concerns about competitive pressures or a slowdown in adoption. The recent pattern of reaffirmed Overweight ratings from multiple firms signals strong conviction in the stock's upside, but the wide range highlights the speculative nature of the valuation at current levels.
Bulls vs Bears: HNGE Investment Factors
Hinge Health presents a compelling growth story with accelerating revenue, expanding margins, and a recent transition to profitability. The bull case is supported by strong analyst conviction and a proprietary AI moat. However, the premium valuation and high volatility introduce significant risk. Currently, the bull case has stronger evidence given the fundamental improvements and market momentum, but the key tension is whether the company can sustain its high growth rate to justify the premium multiple. If growth decelerates or competition intensifies, the stock could face a sharp correction.
Bullish
- Revenue growth accelerating: Q1 2026 revenue of $182.3M grew 47.2% YoY, up from $123.8M in Q1 2025, with sequential acceleration from $170.7M in Q4 2025. This demonstrates strong market demand and successful execution of the growth strategy.
- Profitability achieved: Net income turned positive at $35.1M in Q1 2026, a dramatic swing from the $575.7M loss in Q2 2025 (which included a one-time charge). Operating margin reached 17.6%, indicating a successful pivot to sustainable profitability.
- Gross margin expansion: Gross margin improved to 84.6% in Q1 2026 from 70.3% in Q2 2025, reflecting strong operating leverage and cost management. This high margin provides a solid foundation for future profitability.
- Strong analyst conviction: With 15 analysts, the consensus rating is 'Buy' (mean 1.56) and the average target price of $106.47 implies 20.4% upside from the current price of $88.42. The high target of $140 suggests significant upside potential.
Bearish
- Premium valuation: The PS ratio of 6.26 and EV/Sales of 9.06 are elevated compared to industry averages, indicating the market is pricing in high growth expectations. Any slowdown could lead to multiple compression.
- Recent price volatility: The stock experienced a -48.52% max drawdown and recently pulled back from $93.13 to $88.42, showing high volatility. The short ratio of 3.78 suggests significant short interest, adding to downside risk.
- Dependence on continued growth: With a forward PE of 28.25, the valuation relies on sustained high growth. If revenue growth decelerates below 30%, the stock could face significant de-rating.
- Competitive pressures: The digital MSK market is attracting new entrants, and the low analyst target of $85 (below current price) suggests some analysts see downside risk from competitive disruption or slower adoption.
HNGE Technical Analysis
Hinge Health is in a powerful sustained uptrend, with the stock up 57.89% over the past year and currently trading at $88.42, which is 94.9% of its 52-week range (low of $30.08, high of $93.13). This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of overextension. The stock's 6-month return of 114.04% and YTD return of 94.07% underscore the strength of the longer-term trend, which has been consistently upward since its IPO in May 2025.
Beta
—
—
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$30-$96
Price range past year
Annual Return
+51.3%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +17.9% | +5.5% |
| 3m | +55.4% | +1.7% |
| 6m | +104.3% | +12.2% |
| 1y | +51.3% | +18.6% |
| ytd | +91.7% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue trajectory is accelerating impressively, with Q1 2026 revenue of $182.3 million, up 47.23% year-over-year, and sequential growth from $170.7 million in Q4 2025 and $154.2 million in Q3 2025. The company has also achieved profitability, reporting net income of $35.1 million in Q1 2026, a dramatic turnaround from the $575.7 million loss in Q2 2025, driven by a one-time charge. Gross margin expanded to 84.6% in Q1 2026, up from 70.3% in Q2 2025, reflecting improved operating leverage and cost management. Operating income turned positive at $32.1 million in Q1 2026, with an operating margin of 17.6%, a significant improvement from the -417.5% margin in Q2 2025, indicating a successful pivot to profitability.
Quarterly Revenue
$182307000.0B
2026-03
Revenue YoY Growth
+47.2%
YoY Comparison
Gross Margin
84.6%
Latest Quarter
Free Cash Flow
$206166000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Given the company's positive net income in the most recent quarter, the trailing PE ratio is -8.67 (due to historical losses), but the forward PE of 28.25 is more relevant, indicating the market expects continued earnings growth. The PS ratio of 6.26 is elevated compared to the industry average, suggesting a premium valuation that reflects the company's high growth and improving margins. The EV/Sales ratio of 9.06 further underscores the premium, but this is justified by the company's 47% revenue growth and expanding profitability, which are superior to typical healthcare IT peers.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's reliance on continued high growth to justify its valuation. With a forward PE of 28.25 and PS of 6.26, any slowdown in revenue growth could trigger multiple compression. The company has a low debt-to-equity ratio of 0.02, but its current ratio of 1.47 suggests adequate liquidity. However, the historical net margin of -89.9% (TTM) reflects past losses, though recent quarters show improvement. The company's profitability is still nascent, and any margin erosion could impact investor confidence.
FAQ
The key risks include: 1) Valuation risk - the premium multiple could compress if growth slows, leading to a significant price decline. 2) Competitive risk - new entrants in the digital MSK market could erode market share. 3) Market risk - the stock is highly volatile (beta >1) and could decline in a market downturn. 4) Company-specific risk - dependence on continued revenue growth and margin expansion. The most severe risk is a growth deceleration, which could lead to a -66% decline to the 52-week low.
The 12-month forecast is bullish, with a base case target of $95-$115 (50% probability), a bull case of $120-$140 (30% probability), and a bear case of $70-$85 (20% probability). The most likely scenario is the base case, assuming revenue growth remains above 40% and margins continue to expand. The average analyst target is $106.47, implying 20.4% upside from the current price of $88.42.
HNGE is trading at a premium valuation with a PS ratio of 6.26 and forward PE of 28.25, which is higher than the industry average. This premium is justified by the company's 47% revenue growth and expanding margins. The market is pricing in continued high growth and profitability improvements. Relative to its own history, the stock is near its 52-week high, indicating high investor confidence. Overall, it is fairly valued given its growth prospects, but any slowdown could make it overvalued.
HNGE is a good buy for investors with a high risk tolerance and a long-term horizon. The stock offers 20.4% upside to the average analyst target of $106.47, and the company is growing revenue at 47% YoY with improving profitability. However, the premium valuation (PS 6.26) and high volatility (max drawdown -48.5%) mean it's not suitable for conservative investors. A good entry point would be on any pullback toward the $80 level.
HNGE is more suitable for long-term investment given its high growth stage and volatility. The company is in the early stages of scaling its digital MSK platform, and the AI moat could drive sustained growth over several years. Short-term trading is possible given the stock's momentum, but the high volatility (max drawdown -48.5%) makes it risky. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and to ride out market fluctuations.